PARIS, 18 Oct (APM) - Sanofi, which is at the forefront of bio-production, is making its industrial revolution, Le Figaro (p24) and Les Echos (p19) report on Friday.
In Boston, Sanofi is changing its strategy so that its researchers focus solely on projects with high potential.
Paul Hudson, who took over as chief executive Sanofi on 1 September, officially opened on Tuesday in Framingham, a state-of-the-art, fully digital plant (APMHE 64723
From 2020, it will manufacture biological drugs, approved by the U.S. health authorities.
These are drugs manufactured from a living cell or organism that require other technologies and other quality and traceability standards. The investment amounts to €290 million.
"With this factory, we are taking a step into the future. I hope this is the beginning of a revolution that will transform medicine," Hudson said.
Psoriasis at the core of industrial battle
Psoriasis is at the core of an industrial battle between pharmaceuticals companies, reported Les Echos on Monday (p23).
A new generation of medicines, which still has to show proof, has emerged over the past 20 years, the article reminds. Seriously affected patients have had their symptoms erased.
This new class of treatments, targeting one inflammatory mechanism (IL23), must, however, prove its worth compared to the previous one - which targeted another mechanism (IL17) with already very good results.
For the companies, which produced different generations, such as AbbVie or Janssen, the stake is to succeed in transferring their former prescriptions to the new ones, to avoid losing market share.
Paracetamol boxes no longer in 'open access' in community pharmacies
Paracetamol boxes will no longer be accessible in community pharmacies, reported Le Parisien on Monday, quoting specifically Sanofi's Doliprane (p17).
The paper explains that France's biggest-selling painkiller is linked to liver toxicity when misused. In October, French drug regulator ANSM announced it is willing to allow paracetamol boxes to be behind pharmacy counters.
Last year, one billion boxes of paracetamol were sold, 84% of which were on prescription.
Sofinnova Partners raised €333 million for early-stage therapeutics
Sofinnova Partners has raised €333 million in a new fund for early-stage therapeutic projects, Le Figaro reported on Thursday (p22).
The new fund will be named Capital IX and will be dedicated to health issues.
"This is the biggest fund we will manage in life sciences," its chair Antoine Papiernik said.
Ipsen invests $535 million for potential molecule in rare bone disease
Ipsen is investing $535 million in a potential molecule for a rare bone disease, Le Figaro reported on Thursday (p22).
"Our strategy has been to build a leading rare diseases franchise," said Ipsen's chief executive David Meek (APMHE 64744
). In February, the company bought Canadian biotech Clementia Pharmaceuticals for €1.3 billion.
Start-up Posos raises €2 million
Posos, a start-up which aims to avoid medication errors, has raised €2 million, Les Echos reported on Tuesday.
The company was created two years ago by Olivier Richart, Selenium Medical president and a group of private investors.
The algorithm, developed by Posos, aims to find, in the medical literature the most relevant information, in order to choose the best treatment.
Chiesi's asthma treatment Innovair Nexthaler will be produced in France
Chiesi's asthma treatment Innovair Nexthaler will be produced in France, Les Echos reported on Tuesday (p26).
The Italian company chose to invest €50 million in France to extend its factory at La Chaussée-Saint-Victor, near Blois in the centre of France.
Gattefossé to establish production lines in Texas and Spain
Producer of pharmaceutical excipients company, Gattefossé, will establish production lines in Texas and Spain, Les Echos reported on Wednesday (p27).
Gattefossé, established in Lyon, will invest €5 million in a first production line in Texas, and will hire 15 workers.
The company will also boost its presence in Spain by establishing a new line in Saragosse.
Axorus creates an artificial retina using electronic neuron
Start-up Axorus is creating an artificial retina using an electronic neuron, 20Minutes (p17) reports on Friday.
They aim to enable people with retinal diseases, particularly age-related macular deficiency (AMD), to regain good visual acuity.
However, the scope of their technology should be much broader.
GSK's team in France reshaped
Joséphine Yang Comiskey is leaving a distinctive mark as GSK France president, reported le Figaro on Monday (p32).
The newspaper reviewed GSK's France team and profiles the four chief managers: general secretary Jean-Yves Lecoq, senior finance director Loïc Moreau, medical director Sophie Muller and director of the business Speciality care Alexandre Gustin,